AAV2 Variant Capsids for Retina and Trabecular Meshwork Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing adeno-associated dependoparvoviruses (AAVs) face challenges in achieving efficient and targeted ocular transduction, particularly in specific tissues like the retina and trabecular meshwork, limiting their effectiveness in delivering payloads for therapeutic applications.
Innovation Solution
Development of variant capsid polypeptides with specific mutations, such as VAR-1 to VAR-16, which enhance the transduction efficiency and specificity in ocular tissues by modifying the capsid proteins of AAV2, leading to increased delivery of payloads to regions like the retina and trabecular meshwork.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If wild-type AAV2 capsid is used, then the virus can infect cells, but the ocular transduction efficiency is insufficient and cannot effectively target specific ocular tissues like retina and trabecular meshwork
Solution Approach 1:
The patent applies local quality by introducing specific point mutations at defined positions (e.g., positions 550, 559, 561, 586, 587, 592, 593, 597) in the capsid protein sequence to enhance binding affinity to ocular tissue receptors. This localized modification approach allows the virus to maintain general infectivity while gaining specific targeting capability for ocular tissues such as retina and trabecular meshwork.
Solution Approach 2:
The patent employs parameter changes by systematically varying amino acid residues at specific positions in the capsid protein to optimize transduction efficiency. Multiple variants (VAR-1 to VAR-16) are generated with different combinations of mutations, allowing selection of optimal configurations that maximize ocular tissue targeting while maintaining viral stability and infectivity.
2Productivity
If capsid mutations are introduced to enhance ocular targeting, then transduction efficiency in specific tissues increases, but the complexity of virus production and characterization increases
Solution Approach 1:
The patent applies segmentation by dividing the capsid optimization problem into discrete mutation sites (positions 550-597). Each position can be independently mutated and tested, allowing systematic evaluation of individual and combined mutation effects. This modular approach simplifies the characterization process compared to random mutagenesis.
Solution Approach 2:
The patent creates capsid variants that serve multiple functions: maintaining basic viral infectivity, enhancing ocular tissue binding affinity, and enabling specific targeting of different ocular structures (retina, trabecular meshwork). The conserved mutation pattern across variants provides universal benefits for ocular gene therapy while allowing tissue-specific optimization.
Data Source
AI summary
The disclosure is directed in part to variant capsid polypeptides that can be used to deliver payloads.